Get started
Author

Ignasi Pau‐Charles

Observed names: I. Pau-Charles, I. Pau‐Charles, Ignasi Pau-Charles, Pau-Charles, Ignasi
Institution: Almirall (Spain)
ORCID: 0000-0002-7960-7045
Observed ORCID: 0000-0002-7960-7045
OpenAlex ID: A5011328723
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm®- and placebo-controlled trial (BRIDGE)
2016 · U. Mrowietz, J.C. Szepietowski, et al. · British Journal of Dermatology · 156
PDF
Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks
2019 · K. Reich, R.B. Warren, et al. · British Journal of Dermatology · 149
PDF
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
2018 · Jürgen Brück, Ralf Dringen, et al. · Experimental Dermatology · 132
PDF
Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*
2021 · D. Thaci, S. Piaserico, et al. · British Journal of Dermatology · 103
PDF
Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data
2018 · Lilla Landeck, Khusru Asadullah, et al. · Archives of Dermatological Research · 43
PDF
First-line treatment in lymphomatoid papulosis: a retrospective multicentre study
2017 · R. Fernández-de-Misa, B. Hernández-Machín, et al. · Clinical and Experimental Dermatology · 41
PDF
Anti‐ MDA 5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathy
2013 · I. Pau‐Charles, P.J. Moreno, et al. · Journal of the European Academy of Dermatology and Venereology · 28
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2
2022 · A.P. Fernandez, E. Dauden, et al. · Journal of the European Academy of Dermatology and Venereology · 26
PDF
Quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate ( DMF ): a post hoc analysis of the BRIDGE study
2019 · P.C.M. van de Kerkhof, R. Loewe, et al. · Journal of the European Academy of Dermatology and Venereology · 23
PDF
Infliximab therapy failure in two patients with pemphigus vulgaris
2012 · Ana García-Rabasco, Mercè Alsina-Gibert, et al. · Journal of the American Academy of Dermatology · 23
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
2024 · Jennifer Soung, Sonja Ständer, et al. · Journal of Dermatological Treatment · 17
PDF
Signos cutáneos del maltrato infantil
2011 · I. Pau-Charles, E. Darwich-Soliva, et al. · Actas Dermo-Sifiliográficas · 12
Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis
2025 · Jenny E. Murase, Kilian Eyerich, et al. · Journal of Dermatological Treatment · 11
PDF
High-risk alpha-human papillomavirus types: Detection in HIV-infected children with acquired epidermodysplasia verruciformis
2013 · Asunción Vicente, Ignasi Pau-Charles, et al. · Journal of the American Academy of Dermatology · 10
PDF
Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020
2021 · Ulrich Mrowietz, Peter Van De Kerkhof, et al. · Expert Review of Clinical Immunology · 9
PDF
Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice
2015 · Adrià Gual, Ignasi Pau-Charles, et al. · Journal of Dermatological Treatment · 9
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
2022 · Esteban Daudén, Pablo de la Cueva, et al. · Dermatology and Therapy · 7
PDF
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate‐to‐severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
2021 · D. Thaçi, D. Jullien, et al. · Journal of the European Academy of Dermatology and Venereology · 6
Multiple inflammatory lesions in an oncology patient
2015 · Ramon Pigem, Lidia Maroñas‐Jiménez, et al. · International Journal of Dermatology · 4
Skin Signs in Child Abuse
2012 · I. Pau-Charles, E. Darwich-Soliva, et al. · Actas Dermo-Sifiliográficas · 4
PDF
517 - Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis
2024 · Andrew Alexis, Michael Ardern-Jones, et al. · British Journal of Dermatology · 3
13632 Long-term safety of tildrakizumab in patients 65 years of age or older with moderate to severe psoriasis: Pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials
2020 · Peter C. van de Kerkhof, Esteban Daudén, et al. · Journal of the American Academy of Dermatology · 3
Disseminated cutaneous leishmaniasis in a patient with Sézary syndrome
2014 · Priscila Giavedoni, Ignasi Pau-Charles, et al. · Journal of the American Academy of Dermatology · 3
Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo
2023 · Jenny E. Murase, Monica Munera-Campos, et al. · SKIN The Journal of Cutaneous Medicine · 2
PDF
382 Lebrikizumab provides clinically meaningful improvements in atopic dermatitis in patients previously treated with dupilumab
2023 · Linda Stein Gold, Jan Gutermuth, et al. · British Journal of Dermatology · 2
Works count: 42
Citation count: 828
H-index: 12
I10-index: 14
Year
Topic
Type